IFNG and psoriasis vulgaris: and IFN-γ by blocking intracellular signaling of pro-inflammatory factors such as IL-6, IL-12, IL-23, and IFN-γ [397], significantly improved Disease Activity Score (DAS28-CRP), HAQ-DI, and patient-reported pain, dysfunction, and ruxolitinib demonstrated significant improvement in fatigue symptoms in Phase III RA clinical trials, including the RA-BEAM and RA-BUILD studies [398, 399], furthermore, in a Phase IIb clinical trial, ruxolitinib demonstrated significant efficacy in plaque psoriasis treatment, as evidenced by improved Psoriasis Area and Severity Index 75 response rates [399].